ANXA2 and neoplasm: According to a study by Kim et al. (2020), the authors showed for the first time that, within the TME, a listeria vaccine-based ANXA2-targeting cancer immunotherapy (Lm-ANXA2) was capable of inducing tumor epitope-specific CD8+ T cell response and sensitizing the PDAC tumor to checkpoint inhibitor therapy [94].